Clinical trial · Observational
Breathomics: May it Become an Affordable, New Tool for Early Diagnosis and Screening of Lung Cancer?
Breathomics: May it Become an Affordable, New Tool for Early Diagnosis and Screening of Lung Cancer? An Exploratory Study on a Cohort of 60 Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Breath analysis examining specific patterns of volatile organic compounds (VOCs) has been demonstrated to be able to discriminate lung cancer (LC) patients from healthy controls (HC). However, the existing technology uses complex, expensive, and low throughput analytical platforms to give an offline response, thus preventing its applicability for mass screening. The reliability of a new portable device to enable rapid, on-site LC diagnosis is tested.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Portable GC device for brath analysis | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Lung Cancer Patients
- description
- patients undergoing surgery for histologically proven NSCLC
- interventionNames
- Device: Portable GC device for brath analysis
- label
- Healthy Control Patients
- description
- patients undergoing surgery for benign extra-thoracic disease who had undergone chest X-rays/chest CT-scan, proved to be negative during preoperative evaluation.
- interventionNames
- Device: Portable GC device for brath analysis
Primary outcomes (1)
- measure
- Changes in VOCs peaks in patients with lung cancer vs healthy patients
- timeFrame
- 24 hours
- description
- Identify biomarkers able to discriminate between lung cancer patients and healthy controls.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * NSCLC histologically proven (for LC group) at any stage of disease * non-cancer controls who had negative findings on preoperative chest X-rays/chest CT scan (for HC groups) Exclusion Criteria: * Patients who had any history of another type of cancer * who had received neoadjuvant chemo/radiotherapy because of the possible unknown effects on cancer metabolism * pediatric patients.
References
Publications (1)
- DERIVEDBrascia D, De Iaco G, Panza T, Signore F, Carleo G, Zang W, Sharma R, Riahi P, Scott J, Fan X, Marulli G. Breathomics: may it become an affordable, new tool for early diagnosis of non-small-cell lung cancer? An exploratory study on a cohort of 60 patients. Interdiscip Cardiovasc Thorac Surg. 2024 Sep 4;39(3):ivae149. doi: 10.1093/icvts/ivae149. PMID 39226187